Desmopressin

CHEMBL1429 Phase 4 Approved Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1069.2 g/mol
LogP
-4.0
Phase
4

A synthetic analogue of antidiuretic hormone (ADH/vasopressin) that promotes water reabsorption in the kidney, used to treat central diabetes insipidus, nocturnal enuresis (bedwetting), and von Willebrand disease. It has greater antidiuretic potency and longer duration than natural vasopressin.

Molecular Weight

1069.2000 g/mol

LogP

-4.00

TPSA

489.00 Ų

Lipinski RO5

Fail

Therapeutic Areas

Mechanism of Action

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O

InChI

InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1

Molecular Formula

C46H64N14O12S2

HBD / HBA

13 / 15

Rotatable Bonds

19

Heavy Atoms

74

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A synthetic analogue of antidiuretic hormone (ADH/vasopressin) that promotes water reabsorption in the kidney, used to treat central diabetes insipidus, nocturnal enuresis (bedwetting), and von Willebrand disease. It has greater antidiuretic potency and longer duration than natural vasopressin.

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Yes, Desmopressin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1429. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5311065. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.